INTERTRADE CO.,Ltd. (3747) Stock Price

InterTrade is a company that develops systems supporting securities, foreign exchange, and cryptocurrency trading, while also developing and selling IT tools for businesses and health-related products. Its core business is designing, building, and maintaining trading platforms. In addition to this, the company handles management solutions for business clients and develops health foods and cosmetics.

The company's main customers include financial institutions, securities firms, and FX operators engaged in trading businesses, as well as corporate IT departments, group companies, and general consumers. Revenue comes from system development and implementation contracts, ongoing operation and maintenance contracts, software and service sales, and health food and cosmetics sales.

The business is divided into three main segments: Financial Solutions, Business Solutions, and Healthcare. In Financial Solutions, the company develops and maintains platforms for securities dealing, FX, and cryptocurrency trading. In Business Solutions, it provides IT support and group management tools with implementation assistance. In Healthcare, it plans and sells health foods and cosmetics using functional ingredients derived from Hanabiratake mushrooms.

InterTrade is positioning "Spider Digital Transfer" as its revenue cornerstone and aims to transition into a growth phase by establishing a stable order base across three sectors: financial solutions, business solutions, and healthcare. Financially, the company maintains a solid foundation with an equity ratio of 72.6% and a quick ratio of 321.1%. Going forward, the company plans to strengthen partnerships with financial institutions and explore diverse funding options to make strategic investments as business expands.

Priority investment areas are the next-generation infrastructure "Spider Digital Transfer," the enterprise management solution "GroupMAN@IT e²," and healthcare functional ingredient products. Spider is an infrastructure incorporating blockchain concepts with proven adoption by major trading companies, and the company is strengthening development and sales efforts to make this a core differentiator. GroupMAN@IT e² targets stable revenue through expanded client adoption, while Hanabiratake-derived products will differentiate through scientific evidence backed by Consumer Affairs Agency functional labeling (acquired March 2025).

For new market development, the company is expanding beyond traditional securities and FX firms to reach diverse industries including corporations and trading companies. Specifically, Spider will be offered to non-financial businesses targeting large-scale deployments, while GroupMAN@IT e² will accelerate adoption through standardized implementation packages and enhanced support systems. The healthcare division targets perimenopausal women, aiming to build brand awareness through information disclosure using clinical data and research papers, alongside expanded direct-to-consumer and partner channel sales.

For technological innovation, the company prioritizes securing hybrid talent with strengths in both finance and technology, and improving cross-departmental talent mobility. It will implement systematic knowledge-sharing programs between senior and junior engineers, and advance development process automation, architecture modernization, and security enhancements to achieve both development speed and quality. The company also strengthens external partnerships in R&D and clinical validation, aiming to enhance competitive advantage through both technology and evidence.